Binder J, Kalafat E, Palmrich P, et al. - Via performing this retrospective analysis of prospectively obtained data of pregnant women with chronic hypertension and suspected preeclampsia, researchers herein examined the predictive accuracy of maternal serum sFlt-1, PlGF and their ratio for predicting adverse maternal and perinatal outcomes in women with chronic hypertension. They included a total of 145 women with chronic hypertension and suspected superimposed preeclampsia; 26 of these (17.9%) women developed complications (ie composite adverse maternal or fetal outcome) within 1 week of assessment (gestational age at assessment: 29.9 weeks) and 35 (24.1%) developed complications at any time (gestational age at assessment: 30.1 weeks). In women who developed complications at any time, the median maternal serum sFlt-1/PlGF ratio was 149.4 vs 8.0 in women who did not develop complications. Findings suggest superiority of maternal serum angiogenic markers to clinical assessment in predicting adverse maternal and perinatal outcomes in these women. Seemingly, repeat measurements of the sFlt-1/PlGF ratio are beneficial, given the better predictive accuracy compared with single measurement alone. Implementation of the use of angiogenic makers is recommended in clinical management guidelines of pregnant women with chronic hypertension.